116 related articles for article (PubMed ID: 24435746)
1. Prostate cell lines as models for biomarker discovery: performance of current markers and the search for new biomarkers.
Johnson IR; Parkinson-Lawrence EJ; Butler LM; Brooks DA
Prostate; 2014 May; 74(5):547-60. PubMed ID: 24435746
[TBL] [Abstract][Full Text] [Related]
2. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis of N-linked human glycoproteomic data sets reveals PTPRF ectodomain as a novel plasma biomarker candidate for prostate cancer.
Whitmore TE; Peterson A; Holzman T; Eastham A; Amon L; McIntosh M; Ozinsky A; Nelson PS; Martin DB
J Proteome Res; 2012 May; 11(5):2653-65. PubMed ID: 22494190
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs and zinc metabolism-related gene expression in prostate cancer cell lines treated with zinc(II) ions.
Hlavna M; Raudenska M; Hudcova K; Gumulec J; Sztalmachova M; Tanhäuserova V; Babula P; Adam V; Eckschlager T; Kizek R; Masarik M
Int J Oncol; 2012 Dec; 41(6):2237-44. PubMed ID: 23064315
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Sardana G; Jung K; Stephan C; Diamandis EP
J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
[TBL] [Abstract][Full Text] [Related]
8. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.
Thomadaki H; Mavridis K; Talieri M; Scorilas A
Thromb Haemost; 2009 Feb; 101(2):373-80. PubMed ID: 19190824
[TBL] [Abstract][Full Text] [Related]
9. The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B.
Ren K; Gou X; Xiao M; Wang M; Liu C; Tang Z; He W
Prostate; 2013 Sep; 73(13):1462-9. PubMed ID: 23813671
[TBL] [Abstract][Full Text] [Related]
10. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition.
Coppola V; Musumeci M; Patrizii M; Cannistraci A; Addario A; Maugeri-Saccà M; Biffoni M; Francescangeli F; Cordenonsi M; Piccolo S; Memeo L; Pagliuca A; Muto G; Zeuner A; De Maria R; Bonci D
Oncogene; 2013 Apr; 32(14):1843-53. PubMed ID: 22614007
[TBL] [Abstract][Full Text] [Related]
11. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill.
Bromfield GP; Meng A; Warde P; Bristow RG
Prostate Cancer Prostatic Dis; 2003; 6(1):73-85. PubMed ID: 12664070
[TBL] [Abstract][Full Text] [Related]
12. Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer.
Davies G; Ablin RJ; Mason MD; Jiang WG
J Exp Ther Oncol; 2007; 6(3):257-64. PubMed ID: 17552366
[TBL] [Abstract][Full Text] [Related]
13. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
14. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
[TBL] [Abstract][Full Text] [Related]
15. Altered endosome biogenesis in prostate cancer has biomarker potential.
Johnson IR; Parkinson-Lawrence EJ; Shandala T; Weigert R; Butler LM; Brooks DA
Mol Cancer Res; 2014 Dec; 12(12):1851-62. PubMed ID: 25080433
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic significance of overexpression of Golgi membrane protein 1 in prostate cancer.
Li W; Wang X; Li B; Lu J; Chen G
Urology; 2012 Oct; 80(4):952.e1-7. PubMed ID: 22840862
[TBL] [Abstract][Full Text] [Related]
17. The role of tissue microarrays in prostate cancer biomarker discovery.
Datta MW; True LD; Nelson PS; Amin MB
Adv Anat Pathol; 2007 Nov; 14(6):408-18. PubMed ID: 18049130
[TBL] [Abstract][Full Text] [Related]
18. Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.
Mavridis K; Stravodimos K; Scorilas A
Prostate; 2013 Aug; 73(11):1191-201. PubMed ID: 23620432
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells.
Lin MF; Lee MS; Zhou XW; Andressen JC; Meng TC; Johansson SL; West WW; Taylor RJ; Anderson JR; Lin FF
J Urol; 2001 Nov; 166(5):1943-50. PubMed ID: 11586265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
